𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis

✍ Scribed by Zhe Jin; Yuriko Mori; James P. Hamilton; Alexandru Olaru; Fumiaki Sato; Jian Yang; Tetsuo Ito; Takatsugu Kan; Rachana Agarwal; Stephen J. Meltzer


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
235 KB
Volume
112
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

The promoter of somatostatin (SST), a primary inhibitor of gastrin‐stimulated gastric acid secretion, is hypermethylated in 80% of human colon cancers. The aim of the current study was to investigate whether and at what stage promoter hypermethylation of SST is involved in human esophageal carcinogenesis.

METHODS.

SST promoter hypermethylation was examined by real‐time methylation‐specific polymerase chain reaction (PCR) (MSP) in 260 human esophageal tissue specimens. Real‐time reverse‐transcriptase PCR and MSP were also performed on esophageal cancer cell lines before and after treatment with 5‐aza‐2′‐deoxycytidine (5‐Aza‐dC).

RESULTS.

SST hypermethylation showed highly discriminative receiver‐operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC) from normal esophagus (NE) (P < .01). Both SST methylation frequency and normalized methylation value (NMV) were significantly higher in Barrett metaplasia without dysplasia or EAC (BE), low‐grade and high‐grade (HGD) dysplasia occurring in BE, EAC, and ESCC than in NE (P < .01). SST hypermethylation frequency was significantly lower in NE (9%) than in BE (70%), HGD (71.4%), or EAC (71.6%), whereas 14 (53.8%) of 26 ESCCs exhibited SST hypermethylation. There was a significant relation between SST hypermethylation and BE segment length, a known clinical risk factor for neoplastic progression. Demethylation of KYSE220 ESCC and OE33 EAC cells with 5‐Aza‐dC reduced SST methylation and increased SST mRNA expression. SST mRNA levels in native unmethylated EACs were significantly higher than in native methylated EACs (P < .05).

CONCLUSIONS.

SST promoter hypermethylation is a common event in human esophageal carcinomas and is related to early neoplastic progression in Barrett esophagus. Cancer 2008. © 2007 American Cancer Society.


📜 SIMILAR VOLUMES


Promoter hypermethylation of CDH13 is a
✍ Zhe Jin; Yulan Cheng; Alexandru Olaru; Takatsugu Kan; Jian Yang; Bogdan Paun; Te 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 208 KB

## Abstract Although the __CDH13__ gene has been shown to undergo epigenetic silencing by promoter methylation in many types of tumors, hypermethylation of this gene in Barrett's‐associated esophageal adenocarcinogenesis has not been studied. Two hundred fifty‐nine human esophageal tissues were the

CADM1/TSLC1 inactivation by promoter hyp
✍ Kequan Chen; Guanghai Wang; Liang Peng; Side Liu; Xiangsheng Fu; Yu Zhou; Haishe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 410 KB

## Abstract Cell adhesion molecule 1 (CADM1/TSLC1), a putative tumor suppressor involving in cell adhesion, proliferation and apoptosis, is frequently inactivated in several carcinomas due to promoter hypermethylation. But alterations of CADM1/TSLC1 in colorectal carcinogenesis and clinical signifi

Homozygosity for a Common Polymorphism i
✍ Zaidi, F.K.; Wareham, N.J.; McCarthy, M.I.; Holdstock, J.; Kalloo-Hosein, H.; Kr 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

A commonly occurring sequence variant in the islet-specific promoter of the glucokinase gene (-30 G to A) has been variably reported to be associated with reduced insulin secretory responses to oral glucose. The effect of this promoter variant may be subtle and only become apparent under conditions